Further clinical trial modifications are required still to determine the optimal dose of NKG2D CAR-T cells in AML patients, and whether combination with HMAs could augment NKG2D CAR-T cells expansion or upregulation of NKG2DLs expression in AML cells for NKG2D CAR-T cells recognition is an open question. The gene discussed is KLRK1; the disease is acute myeloid leukemia.